Navigation Links
Arius announces leading independent proxy firm, RiskMetrics ISS Canada, recommends shareholders vote for the arrangement involving its acquisition by Roche
Date:9/9/2008

TORONTO, Sept. 9 /PRNewswire-FirstCall/ - ARIUS Research Inc., (TSX: ARI), a biotechnology company discovering and developing the next wave of antibody therapeutics, today announced that RiskMetrics ISS Canada, Canada's leading independent proxy firm, has indicated that they have no objection to the transaction, and are recommending that ARIUS shareholders and warrant holders vote FOR the proposed plan of arrangement whereby Roche will acquire all of ARIUS' outstanding shares and warrants.

"The comprehensive review undertaken by RiskMetrics ISS Canada recommends that ARIUS shareholders and warrant holders vote FOR the Arrangement and, in our opinion, provides significant independent validation that the transaction represents the best option for maximizing shareholder value," said Dr. David S. Young, President and Chief Executive Officer of ARIUS.

A special meeting of ARIUS shareholders and warrant holders will be held at 10:30 a.m. Eastern Time on September 16, 2008 at the Suites at 1 King West, Toronto, Ontario, Canada, M5H 1A1. ARIUS shareholders and warrant holders are encouraged to review the Notice of Special Meeting and Information Circular issued by the Company on August 12, 2008. The Information Circular provides, among other things, a detailed discussion of the process that led to the proposed Arrangement and the reasons behind ARIUS Board of Directors' unanimous recommendation that shareholders vote FOR the transaction. Pending the receipt of court and shareholder approval, the transaction is expected to be completed in late September.

ARIUS' Board asks shareholders and warrant holders to vote their proxy FOR the proposed Arrangement today by signing, dating and returning their proxies. The deadline for receiving proxies is September 12, 2008 at 5:00 p.m. Eastern Time. If shareholders have any questions about the information contained in the Information Circular or require assistance in completing their proxy forms, please contact ARIUS' proxy solicitation agent, The Laurel Hill Advisory Group, toll-free at 1-888-270-2614.

About ARIUS

ARIUS is a biotechnology company discovering and developing the next wave of antibody therapeutics. Established in 1999, ARIUS has built a proprietary technology platform, FunctionFIRST(TM), that rapidly identifies and selects antibodies based on their functional ability to affect disease. This antibody generation engine has enabled ARIUS to assemble a portfolio of more than 500 antibody candidates. In addition to the antibodies it is developing in-house, ARIUS has ongoing partnerships with key biotechnology and drug development companies. ARIUS is listed on the TSX under the symbol "ARI". For further information, visit http://www.ariusmabs.com

Forward-Looking Statements

Certain statements in this news release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements in this release include, but are not limited to, ARIUS successfully advancing its new product programs as well as licensing opportunities. These statements are only predictions and actual events or results may differ materially. Factors that could cause such actual events or results expressed or implied by such forward-looking statements to differ materially from any future results expressed or implied by such statements include, but are not limited to: early stage of development; technology and product development; dependence on and management of current and future corporate collaborations; future capital needs; uncertainty of additional funding; no assurance of market acceptance; dependence on proprietary technology and uncertainty of patent protection; intense competition; manufacturing and market uncertainties; and government regulation. These and other factors are described in detail in ARIUS' Annual Report, forthcoming news releases and other filings with Canadian securities regulatory authorities available at http://www.sedar.com. Forward-looking statements are based on our current expectations and ARIUS is not obligated to update such information to reflect later events or developments.

The TSX has not reviewed and does not accept responsibility for the

adequacy or accuracy of this statement.


'/>"/>
SOURCE ARIUS Research Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Darius Naigamwalla Appointed Senior Vice President and Head of the Brand Management Practice at Campbell Alliance
2. Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeutics
3. ARIUS announces second quarter fiscal 2008 financial results
4. ARIUS presents new findings for anti-cancer antibody programs at AACR
5. ARIUS announces first quarter fiscal 2008 financial results
6. ARIUS 2008 Annual and Special Meeting of Shareholders
7. ARIUS recognized for entrepreneurial excellence
8. ARIUS announces five abstracts selected for presentation at 2008 AACR Annual Meeting
9. ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells
10. Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody
11. ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016  Liquid Biotech USA ... of a Sponsored Research Agreement with The University ... (CTCs) from cancer patients.  The funding will be ... correlate with clinical outcomes in cancer patients undergoing ... then be employed to support the design of ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... While ... machines such as the Cary 5000 and the 6000i models are higher end machines ... is the height of the spectrophotometer’s light beam from the bottom of the cuvette ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... ... 23, 2016 , ... Charm Sciences, Inc. is pleased to ... AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of the ... Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably ...
Breaking Biology Technology:
(Date:6/3/2016)... LONDON , June 3, 2016 /PRNewswire/ ... Transport Management) von Nepal ... ,Angebot und Lieferung hochsicherer geprägter Kennzeichen, einschließlich ... weltweit führend in der Produktion und Implementierung ... an der Ausschreibung im Januar teilgenommen, aber ...
(Date:6/2/2016)...   The Weather Company , an IBM Business (NYSE: ... capability in which consumers will be able to interact with ... via voice or text and receive relevant information about the ... Marketers have long sought an advertising solution that can create ... relevant and valuable; and can scale across millions of interactions ...
(Date:6/1/2016)... NEW YORK , June 1, 2016 ... Biometric Technology in Election Administration and Criminal Identification to ... According to a recently released TechSci Research report, " ... Sector, By Region, Competition Forecast and Opportunities, 2011 - ... $ 24.8 billion by 2021, on account of growing ...
Breaking Biology News(10 mins):